- Home
- SJT vs IPSC Comparison
SJT vs IPSC Comparison
Compare SJT & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- IPSC
- Stock Information
- Founded
- SJT 1980
- IPSC 2019
- Country
- SJT United States
- IPSC United States
- Employees
- SJT N/A
- IPSC N/A
- Industry
- SJT Oil & Gas Production
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- SJT Energy
- IPSC Health Care
- Exchange
- SJT Nasdaq
- IPSC Nasdaq
- Market Cap
- SJT 180.8M
- IPSC 149.1M
- IPO Year
- SJT N/A
- IPSC 2021
- Fundamental
- Price
- SJT $4.03
- IPSC $1.24
- Analyst Decision
- SJT
- IPSC Strong Buy
- Analyst Count
- SJT 0
- IPSC 4
- Target Price
- SJT N/A
- IPSC $13.00
- AVG Volume (30 Days)
- SJT 178.6K
- IPSC 485.8K
- Earning Date
- SJT 11-29-2024
- IPSC 11-05-2024
- Dividend Yield
- SJT 8.60%
- IPSC N/A
- EPS Growth
- SJT N/A
- IPSC N/A
- EPS
- SJT 0.19
- IPSC N/A
- Revenue
- SJT $11,031,594.00
- IPSC $2,684,000.00
- Revenue This Year
- SJT N/A
- IPSC $244.52
- Revenue Next Year
- SJT N/A
- IPSC $27.73
- P/E Ratio
- SJT $20.31
- IPSC N/A
- Revenue Growth
- SJT N/A
- IPSC 7.88
- 52 Week Low
- SJT $3.21
- IPSC $1.14
- 52 Week High
- SJT $7.22
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- SJT 54.55
- IPSC 39.95
- Support Level
- SJT $3.71
- IPSC $1.20
- Resistance Level
- SJT $4.02
- IPSC $1.29
- Average True Range (ATR)
- SJT 0.17
- IPSC 0.12
- MACD
- SJT -0.01
- IPSC -0.00
- Stochastic Oscillator
- SJT 86.49
- IPSC 15.42
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.